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PURPOSE. We determined the phenotypic variation, disease progression, and potential
modifiers of autosomal dominant retinal dystrophies caused by a splice site founder mutation,
c.828þ3A>T, in the PRPH2 gene.
METHODS. A total of 62 individuals (19 families) harboring the PRPH2 c.828þ3A>T mutation,
had phenotype analysis by fundus appearance, electrophysiology, and visual fields. The
PRPH2 haplotypes in trans were sequenced for potential modifying variants and generalized
estimating equations (GEE) used for statistical analysis.
RESULTS. Several distinct phenotypes caused by the PRPH2 c.828þ3A>T mutation were
observed and fell into two clinical categories: Group I (N ¼ 44) with mild pattern dystrophies
(PD) and Group II (N ¼ 18) with more severe cone-rod dystrophy (CRD), retinitis pigmentosa
(RP), and central areolar chorioretinal dystrophy (CACD). The PRPH2 Gln304-Lys310-Asp338
protein haplotype in trans was found in Group I only (29.6% vs. 0%), whereas the Glu304-
Lys310-Gly338 haplotype was predominant in Group II (94.4% vs. 70.4%). Generalized
estimating equations analysis for PD versus the CRD/CACD/RP phenotypes in individuals over
43 years alone with the PRPH2 haplotypes in trans and age as predictors, adjusted for
correlation within families, confirmed a significant effect of haplotype on severity (P ¼ 0.03)
with an estimated odds ratio of 7.16 (95% confidence interval [CI] ¼ [2.8, 18.4]).
CONCLUSIONS. The PRPH2 c.828þ3A>T mutation results in multiple distinct phenotypes likely
modified by protein haplotypes in trans; the odds of having the CACD/RP-like phenotype
(versus the PD phenotype) are 7.16 times greater with a Glu304-Lys310-Gly338 haplotype in
trans. Further functional studies of the modifying haplotypes in trans and PRPH2 splice
variants may offer therapeutic targets.
Keywords: phenotype, genetic modifiers, retinal dystrophy
Mutations in the PRPH2 gene (OMIM:179605) are known tocause a wide range of autosomal dominant retinal
dystrophies (adRD; phenotype MIM: 613105, 608133,
169150, 608161, 608133, 136880), but the source of this
variation is poorly understood. We previously identified a
PRPH2 (NM_000322.4) splice site mutation, c.828þ3A>T, in
numerous patients with retinal dystrophies.1 Haplotype analy-
sis revealed that the mutation derives from a common ancestor
and its prevalence is due to a founder effect.2 Individuals with
the c.828þ3A>T mutation express a PRPH2 splice variant that
was not found in controls and is consistent with abnormal
splicing. Clinical diagnoses in individuals with this mutation
range from pattern dystrophies (PD) to retinitis pigmentosa
(RP), cone-rod dystrophy (CRD), and/or unspecified macular
dystrophy.2 This phenotypic variation is comparable to other
mutations in PRPH2, for example, a 3-bp deletion of codon
153, and a P210R missense change3 that were reported to cause
multiple phenotypes within the same nuclear families.4
Another PRPH2 mutation, R172W, also exhibits a founder
effect but with similar phenotypes in most families,5,6 although
intrafamilial variation also has been described in two families.7,8
In this study, we evaluated clinical records, fundus
photographs, and visual function data to characterize the
phenotype of the PRPH2 c.828þ3A>T splice site mutation.
Due to the founder effect, this cohort is particularly well suited
for identifying possible causes of variation that are not in cis to
the splice site mutation.
Peripherin/PRPH2 is a photoreceptor-specific membrane
protein that homodimerizes with itself. Polymorphic protein
haplotypes in trans were considered as modifiers of dominant
diseases because the two alleles are expressed at the same time
in the same tissues, translation is concurrent, and protein
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products may follow identical pathways and interact directly.
Therefore, sequence variants in the PRPH2 gene in trans that
code for polymorphic protein isoforms (haplotypes), Glu304-
Lys310-Gly338 (G910-A929-G1013), Gln304-Arg310-Asp338 (C910-G929-
A1013), and Gln304-Lys310-Asp338 (C910-A929-A1013), coded by
three polymorphic cSNPs, rs390659 c.910G>C (GAG->CAG)
p.Glu304Gln, rs425876, c.929A>G (AAG->AGG) p.Lys310Arg,
and rs434102 c.1013G>A (GGC->GAC) p.Gly338Asp were
considered as potential modifiers of the disease pheno-
type.2,9,10
We also considered 3 other candidate genes as modifiers,
ROM1, GUCA1A, and NXNL1. ROM1 is a photoreceptor-
specific gene that encodes a rod outer-membrane protein
localized to the photoreceptor outer segment disk mem-
branes. It has 35% homology to PRPH2 and interacts with
PRPH2-forming heterotetramers.11 Mutations in this gene
alone have not been shown conclusively to cause any retinal
disease, although a digenic form of RP with a PRPH2
mutation has been reported.12 Therefore, ROM1 was
considered as a strong candidate modifier gene, particularly
in individuals with the retinitis pigmentosa phenotype. The
GUCA1A gene encodes a photoreceptor-specific guanylate
cyclase-activator protein, a novel Ca(2þ) binding protein
that stimulates synthesis of cGMP in photoreceptors.13
Mutations in this gene are known to cause autosomal
dominant cone dystrophy, making it a likely modifier
gene.14,15 Another gene, NXNL1, encodes a thioredoxin-like
protein 6, which is specifically expressed in photoreceptors
and required for cone viability.16 We considered GUCA1A
and NXNL1 as potential modifier genes, especially in those
patients exhibiting predominant macular disease and cone
loss.
METHODS
Subjects and Clinical Studies
All subjects were ascertained in the United States after
obtaining written informed consent and all procedures
conformed to the Declaration of Helsinki and were approved
by the Institutional Review Board (IRB) board of each
respective institution as described previously.2 We studied
19 families (FAM) harboring the splice site mutation. Families
1 to 10 were ascertained by David Birch, PhD, at the Retina
Foundation of the Southwest (RFSW; Dallas, TX, USA); Fam11
by Richard Ruiz, MD, at University of Texas Health Science
Center (Houston, TX, USA); Fam12 by Jonathon Sears, MD, at
Cole Eye Institute (Cleveland, OH, USA); Fam13, Fam15, and
Fam17 to Fam19 by Edwin Stone, MD, PhD, at the University
of Iowa (Iowa City, IA, USA); Fam14 at the University of
Oregon (Eugene, OR, USA) by Richard Weleber, MD; and
Fam16 by Gerald Fishman, MD, at the University of Illinois
(Chicago, IL, USA). Screening for sequence variants was
performed at the Molecular Ophthalmology Laboratory at the
University of Iowa and the Laboratory for Molecular Diagnosis
of Inherited Eye Diseases at the University of Texas Health
Science Center.
Clinical findings were analyzed to determine the pheno-
type of the individuals and classify them into defined
diagnostic groups. Fundus photographs were available for
62 individuals from 19 families with the splice site mutation.
To maintain consistent standards, we used electrophysiology
data from RFSW alone for analysis. Electroretinographic
(ERG) data were available for 25 individuals, dark adaptom-
etry for 24 individuals, and Humphrey visual fields for 10
individuals.
Visual Acuity
Best-corrected visual acuity was recorded using an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart or
standard Snellen visual acuity charts.
Visual Fields
Visual fields were tested at RFSW using standard spot size 3,
program 30-2 and/or 60-4 SITA Fast on a Humphrey field
analyzer (Humphrey Instruments, Inc., San Leandro, CA, USA).
Electrophysiology
Patients were dilated using tropicamide 1% and phenylephrine
2.5% and then dark-adapted for 45 minutes before testing.
Usually only the eye with the poorer visual acuity was tested.
The ERG was recorded from the dilated, dark-adapted eye
following the International Society for Clinical Electrophysiol-
ogy of Vision (ISCEV) standards as described previously.17
Dark Adaptometry
Patients’ eyes were dilated using tropicamide 1% and
phenylephrine 2.5% and dark-adapted completely for 45
minutes before testing. Final dark-adapted thresholds were
measured on a Goldmann-Weekers adaptometer according to
standard protocols.18–20
Fundus Photographs
Fundus photographs were obtained from each site whenever
available. Phenotypic classification was based on fundus
findings available in 62 individuals. All individuals with macular
and/or peripheral yellow, orange, or gray (dot and halo)
deposits were grouped into various types of PD as described
previously.21–23 Patients with macular pigmentation and
atrophy preceding peripheral retinal changes were classified
as having CRD.24 If the fundus appeared to have peripheral
intraretinal bone spicules, mottling, and granularity of the RPE,
and/or had optic nerve pallor and retinal vessel attenuation,
patients were classified as having RP.25 Individuals with
symmetric, sharply outlined areas of geographic atrophy of
the RPE and choroid, approximately 3 to 4 disc diameters in
size, and having a yellow-white appearance of the choroidal
vessels, were classified as central areolar chorioretinal dystro-
phy (CACD).26
These diagnoses were combined into two groups to analyze
the effect of modifier genes: Group I – milder phenotype with
PD: The presence of yellow or pigmented lesions in the retina
and/or retinal atrophy confined to the macula alone; and
Group II – more severe phenotype with CRD, RP and CACD:
These were characterized by photoreceptor loss, RPE, and
choroidal atrophy extending outside the macula and/or
presence of intraretinal bone spicules.
Molecular Studies
DNA extraction and screening by SSCP or bidirectional
fluorescent di-deoxy sequencing of the genes, PRPH2
(NM_000322.4) , ROM1 (NM_000327.3) , GUCA1A
(NM_000409.3), and NXNL1 (NM_138454.1) were performed
using standard conditions as described previously.1,27 PRPH2
haplotypes in trans were determined by subtraction of the
known c.828þ3A>T haplotype from the genotype determined
via sequencing. Primers used in the study are available in
Supplementary Table S1.
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Statistical Analysis
Linear regression was used to analyze the relation between age
and visual function parameters in patients with the splice site
PRPH2 mutation. The best-fit values of the slope and intercept,
along with their standard errors and 95% confidence intervals
(CIs), were calculated. Associations between the two pheno-
type groups and the three protein haplotypes in trans were
tested by Fisher’s exact probability test. To confirm that
significant associations were not due to age differences or
familial clustering of genotypes, generalized estimating equa-
tion (GEE) models28 were fit using the ‘‘geepack’’ R package.29
These regressions modeled phenotype group as a function of
haplotype and age via a logistic link, and robustly accounted
for genetic correlation within families. An exchangeable
correlation structure was specified for each familial cluster,
but it is important to note that GEE models are robust even if
the correlation structure is misspecified. For all haplotype
analyses, we excluded all individuals younger than 43 years,
taking into consideration the fact that the youngest age of an
individual with the more severe phenotype in our cohort was
43 years.
RESULTS
The presenting symptoms of the individuals with the
c.828þ3A>T splice site mutation include reduced, altered, or
distorted central vision, sensitivity to bright lights, and reduced
night vision.
Four distinct phenotypes were observed consistent with
PDs, CRD, RP, or CACD with extensive intra- and interfamilial
variation. Three types of PD, adult-onset vitelliform macular
dystrophy (AVMD), butterfly-shaped macular dystrophy (BMD),
and adult-onset flavimaculatus-like macular dystrophy
(AOFMD) of three individuals in their 40s are shown in Figures
1A through 1C. Individuals having AVMD and BMD exhibited a
milder phenotype at age 40 than the individual with AOFMD,
FIGURE 1. Fundus photographs, ERG, and Humphrey visual fields of three PD patients. (A) Adult-onset foveomacular vitelliform-like PD: 46-year-old
female (Fam7-5790) showing lipofuscin deposits in the macula, normal rod and cone responses, very minimal field loss. (B) Butterfly-like PD: 49-
year-old female (Fam1-214) showing lipofusin deposits in the macula and in the periphery, decreased rod and cone responses, moderate peripheral
field loss. (C) Flavimaculatus-like PD: 28-year-old female (Fam2-4957) showing peripheral deposits (seen better in fluorescein inset), decreased rod
responses but normal cone responses, mild peripheral field loss.
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who showed more severe ERG and field loss at age 28 years. A
fluorescein angiogram shows hyperfluorescent lesions that are
not visible by ophthalmoscope (Fig. 1C, inset). The absence of
‘‘dark choroid’’ distinguishes these from Stargardt’s and fundus
flavimaculatus caused by mutations in the ABCA4 gene.30
Individuals with more extensive vision loss, as in CRD, CACD,
and RP phenotypes, are shown in Figures 2A through 2C.
The fundus features of 62 individuals, along with their
diagnoses, age, and sex, and the PRPH2 mini-haplotypes in
trans, are shown in Table 1 and pedigrees for 14 families are
available in the Supplementary Material. Of the individuals, 44
were graded as Group I and had the clinical diagnosis of PD,
and 18 were graded as Group II and had CRD, RP, or CACD.
Age
The age range of our patients was 16 to 90 years, with majority
in the 40- to 50-year range. The youngest individual examined,
a 16-year-old male, had minimal yellow lesions in the
peripheral retina and the oldest individual, a 90-year-old
female, had geographic atrophy in the macula; both belonged
to the same family. The majority of the individuals with the
splice site mutation fell into the PD Group I (44), with ages
ranging from the 20s to the 70s (Table 1). Individuals having a
fundus appearance suggestive of CRD (8), RP (6), and CACD
(4) were in their fifth to sixth decades of life (Table 1).
Visual Acuity
Visual acuity data were available for 46 individuals with the
splice site mutation, and the best-corrected visual acuity of the
better eye was used for plotting (Fig. 3A). Most of the PD
patients retain fairly good visual function, with their acuity
remaining above 20/40 (0.5) until 65 years of age (green
symbols). There was a modest decrease of visual acuity in PD
with age due to photoreceptor and RPE atrophy in the macular
region (Fig. 3A, solid line). In contrast, patients with CACD and
CRD exhibited significantly lower visual acuity (red symbols),
with more than half of the patients over age 45 having VA
below 20/100 (0.2). Retinitis pigmentosa patients had VA
ranging from 20/40 to 20/400 (0.2 to <0.08).
FIGURE 2. Fundus photographs, ERG, and visual fields in more severe retinal dystrophies. (A) Cone-rod dystrophy in a 58-year-old female (Fam1-
212) showing photoreceptor and RPE atrophy, reduced rod and cone responses with central field loss, and relative preservation of the peripheral
field. (B) Central areolar chorioretinal dystrophy in a 56-year-old male (Fam1-309) showing geographic atrophy of photoreceptors, RPE, and
choriocapillaries atrophy, with sparing of peripheral retina with corresponding Goldmann III4e visual field. (C) Retinitis pigmentosa in a 60-year-old
female (Fam8-6138) showing pigmentary changes in the periphery with a generalized loss of photoreceptors and RPE, loss of rod function more
than cone, and peripheral visual field loss with relative central sparing.
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TABLE 1. Phenotype and Haplotypes of PRPH2 Gene in trans to the Splice Site Mutation
No.
Individual
ID
Haplotype
in trans
Age, y
First Visit Sex Phenotype – Clinical Features
1 Fam13-3 C-A-A 16 M PD – few lipofuscin deposits
2 Fam13-35 G-A-G 24 F PD – lipofuscin deposits
3 Fam14-7 C-A-A 25 M PD – few lipofuscin deposits
4 Fam13-68 C-A-A 26 F PD – few lipofuscin deposits
5 Fam5-5738 G-A-G 27 F PD – lipofuscin deposits in macula and ST arcade
6 Fam2-4957 G-A-G 28 F PD – granular appearance in macula, flecks in peripapillary region and
arcades, confluent, pigment þ
7 Fam14-16 G-A-G 30 F PD – lipofuscin deposits in macula and around arcades
8 Fam2-5878 C-A-A 30 M PD – minimal lipofuscin deposits
9 Fam8-6226 G-A-G 35 F PD – grayish yellow lesion in macula with min flecks
10 Fam13-91 G-A-G 37 M PD – minimal macular lesion
11 Fam13-41 G-A-G 38 F PD – subtle adult vitelliform lesions in fovea, lipofuscin accumulation
near the arcades
12 Fam13-92 G-A-G 38 M PD – macular pigmentary changes with peripheral drusen-like subretinal
deposits
13 Fam14-21 G-A-G 39 M PD – yellow deposit in macula with min flecks
14 Fam6-5755 G-A-G 39 M PD – yellow deposit in macula, flecks in peripapillary region and
arcades
15 Fam12-3 C-A-A 40 F PD – yellow deposit in macula, RPE atrophy with flecks
16 Fam7-7082 G-A-G 41 M PD – yellow deposit in macula with min flecks
17 Fam11-3 G-A-G 41 F PD – yellow deposits in macula
18 Fam2-9205 G-A-G 43 M CRD – extensive RPE atrophy in macula, flecks around atrophic zone
19 Fam14-9 G-A-G 45 F PD – pattern-like maculopathy
20 Fam1-177 C-A-A 45 F PD – min Flecks, hypopigmentation in macula
21 Fam14-14 G-A-G 46 F PD – pattern-like maculopathy
22 Fam5-9226 G-A-G 46 F PD – extensive confluent flecks
23 Fam7-5790 C-A-A 46 F PD – vitelliform-like lesion at macula, min flecks
24 Fam13-39 G-A-G 47 F PD – very early pattern lesion in fovea, abnormal lipofuscin deposits
beyond the arcades
25 Fam1-262 G-A-G 48 M RP – extensive atrophy – bone spicules all quadrants
26 Fam12-2 G-A-G 49 M PD – yellow lesion in macula and flecks
27 Fam14-15 G-A-G 49 F PD – pattern-like maculopathy
28 Fam1-214 G-A-G 49 F PD – lipofuscin deposits – macula and periphery
29 Fam1-194 C-A-A 49 F PD – lipofuscin deposits in macula, min flecks
30 Fam7-6221 C-A-A 49 F PD – grayish yellow deposits in macula with min flecks
31 Fam8-9048 G-A-G 50 M PD – multiple flecks, flavimaculatus-like, mottling of RPE
32 Fam2-9207 G-A-G 51 F PD – yellow lesion at macula, min flecks
33 Fam4-5249 G-A-G 51 F PD – gray, yellow lesions in macula, min flecks
34 Fam13-6 G-A-G 53 F CRD – extensive RP and choroidal atrophy in macula and periphery
with bone spicules
35 Fam2-4920 G-A-G 54 F CRD – extensive RP and choroidal atrophy in macula and periphery
with bone spicules
36 Fam12-1 G-A-G 55 F PD – yellow lesions in macula, RPE degeneration with flecks
37 Fam13-18 G-A-G 56 M PD – macular dot and halo lesion, lipofuscin deposits around arcades
38 Fam5-9234 G-A-G 57 F CRD – chorioretinal atrophy in macular region min flecks
39 Fam15-1 G-A-G 57 F RP – initially ad retinal dystrophy with flecks; 2 y later RPE atrophy w/
clumped RPE – pavingstone and photoreceptor degeneration
40 Fam13-1 G-A-G 58 M PD – fleck-like collections of lipofuscin in macula extending beyond
arcade
41 Fam1-302 G-A-G 58 F PD – yellow flecks in macula
42 Fam1-212 G-A-G 58 F CRD – extensive atrophy macular region and around peripapillary
region
43 Fam13-17 G-A-G 59 M PD – large reticular lipofuscin deposits extending from the arcades to
the perifoveal area
44 Fam14-3 G-A-G 59 M CACD – central RPE and choroidal atrophy
45 Fam15-6 G-A-G 59 F PD – lipofuscin deposits, mild arterial attenuation
46 Fam8-6138 G-A-G 60 F RP – macula – hypopigmentation, peripheral BSs, and drusen-like
deposits
47 Fam15-16 G-A-G 61 M CRD – RPE atrophy w/pigment clumps, arterial attenuation, cobblestone
48 Fam13-34 C-A-A 65 F PD – 5-pointed butterfly lesion in macula
49 Fam1-365 G-A-G 65 M PD – yellow-gray lesion with confluent flecks
50 Fam13-87 G-A-G 65 F CACD – multifocal choroidal atrophy, optic atrophy/arterial attenuation
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FIGURE 3. Visual function in patients with PD (solid green circles; solid regression line) and widespread dystrophy (open red circles). (A) Visual
acuity (decimal) as a function of age. (B) Final dark-adapted threshold as a function of age. Dashed line is upper limit of normal. (C) Cone b-wave
amplitude to ISCEV standard 30-Hz flicker. Lines connect repeated measurements in a patient. Solid regression is linear fit to amplitudes for PD.
Dashed line is lower limit of normal (P < 0.05). (D) Rod b-wave amplitude to ISCEV standard flash. Lines connect repeated measurements in a
patient. Solid regression is linear fit to amplitudes for PD. Dashed line is lower limit of normal (P < 0.05).
TABLE 1. Continued
No.
Individual
ID
Haplotype
in trans
Age, y
First Visit Sex Phenotype – Clinical Features
51 Fam11-1 G-A-G 65 F PD – atrophic patches in foveal region with yellow flecks extending to
arcades
52 Fam11-2 G-A-G 67 M PD – RPE atrophy confined to macular area, surrounded by flecks
53 Fam14-1 G-A-G 69 M CACD – central RPE and choroidal atrophy
54 Fam14-17 G-A-G 69 M RP – central RPE and choroidal atrophy and peripheral bone spicules
55 Fam13-60 C-A-A 70 M PD – butterfly lesion in macula and scattered lesions along the arcades
56 Fam6-5809 G-A-G 70 M CACD – central RPE and choroidal atrophy
57 Fam13-93 C-A-A 71 F PD – over 17 y changes from macular lesion to central atrophy
58 Fam13-15 G-A-G 75 F CRD – RPE atrophy macula and peripapillary region along with bone
spicules
59 Fam3-5097 G-A-G 76 F RP – peripheral bone spicules
60 Fam1-178 G-A-G 84 M RP – extensive photoreceptor loss, RPE and choroidal atrophy along
with bone spicules
61 Fam15-14 C-G-A 85 M CRD – atrophy and drusen, lots of hyperplasia, cobblestone, geographic
atrophy
62 Fam13-33 C-A-A 90 F PD – peripheral lipofuscin deposits, peripapillary atrophy and scarring,
as well as geographic atrophy in macula
The age, sex, and fundus appearance of the affected individuals harboring the splice site mutation, and haplotypes in trans, Glu304-Lys310-Gly338
(G910-A929-G1014), Gln304-Arg310-Asp338 (C910-G929-A1014), and Gln304-Lys310-Asp338 (C910-A929-A1014) in exon 3 of PRPH2 are shown. Classification of
the individuals into three phenotypes, PD, CACD, and RP, was based on fundus appearance and other visual function data including ERG and visual
fields when available. Min, minimum.
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Visual Fields
Humphrey visual fields were available in 10 individuals.
Individuals with PD had better visual fields than those with
CRD, CACD, or RP (Figs. 1, 2). Individuals with vitelliform-like
PD had the most well-preserved visual fields (Fig. 1A).
Butterfly-type PD (Fig. 1B) and flavimaculatus-like PD (Fig.
1C) showed preserved central and mild to moderate peripheral
field loss. The CRD and CACD patients had central and
paracentral scotoma (Figs. 2A, 2B) and RP patients had
primarily peripheral visual field loss progressing to loss of
central visual fields as expected (Fig. 2C).
Dark Adaptometry
Final dark-adapted thresholds were available from 24 patients
(Fig. 3B). The majority of patients with PD (green symbols) had
thresholds near the upper limit of normal. Thresholds were
elevated approximately 2 to 4 log units above normal in
individuals with the RP, CRD, and CACD phenotypes (red
symbols).
Electrophysiology
Electroretinographic data were available for 25 individuals,
with many patients tested on multiple occasions. Summary
ERG parameters are shown in Table 2 and Figure 3. In general,
cone responses were affected less than rod responses. As
shown in Figure 3C, patients with PD showed a gradual loss
with age of cone amplitude to 30 Hz flicker. The solid green
curve is the regression line for cone amplitudes as a function of
age on the first visit only. Lines connecting green symbols show
repetitive measures on the same individual, with mild decline
evident between visits, especially after 40 years of age. In
contrast, red symbols show that patients with CRD, CACD, and
RP typically had smaller cone amplitudes than patients with
PD. Cone b-wave implicit times showed greater delays in
patients with more widespread disease than in patients with
PD, where cone implicit times were only slightly delayed.
Figure 3D shows rod amplitudes as a function of age. All
individuals with rod amplitudes significantly below normal (P
< 0.05), with the exception of one individual with PD, had RP,
CRD, or CACD (red symbols). Individuals of various subgroups
of PD did not show any characteristic pattern of photoreceptor
loss. Two individuals who had normal and near-normal
amplitudes had vitelliform-like PD (Fig. 1A, #5790) and
butterfly-like PD (Fig. 1B, #214). These findings suggested
that, although the distribution of flecks results in a varied
fundus appearance, the photoreceptor loss does not corre-
spond to fundus appearance.
Long-term follow-up of some individuals over several years
show differences in severity of progression. Patients with PD
showed milder progressive vision loss (Fig. 4) than patients
with CACD/RP-like phenotype (Fig. 5).
Modifier Gene Screening
Peripherin/PRPH2. The distribution of PRPH2
(NM_000322.4) haplotypes in trans for PD, CRD, CACD, and
RP phenotypes are shown in Tables 3 and 4. For individuals
over 43 years, in Group I, representing milder disease with
different types of PDs, Gln304-Lys310-Asp338 (C910-A929-A1014)
was identified in eight individuals (29.6% vs. 0%) and 19 had
Glu304-Lys310-Gly338 (G910-A929-G1013). In Group II, with CRD,
RP, and CACD, 17 individuals had Glu304-Lys310-Gly338 (G910-
A929-G1013; 94.4% vs. 70.4%), and one had Gln304-Arg310-Asp338
(C910-G929-A1013). Gln304-Lys310-Asp338 (C910-A929-A1013) was
absent (Table 4). A significant difference in the haplotype
distribution between the two phenotypic groups among
individuals older than 43 years was seen using Fisher’s exact
probability test (P¼ 0.0092). A GEE analysis that accounted for
differences in age and familial correlation of genotypes
confirmed that the increased frequency of the Glu304-Lys310-
TABLE 2. Mean and Standard Deviations of ERG Values for Affected (Aff) Individuals Harboring the c.828þ3A>T Splice Site Mutation and Normal
(Nor) Controls Are Shown
Parameters
Aff Nor Aff Nor Aff Nor Aff Nor
Mean Mean SD SD Min Min Max Max
Age at exam 48 14 20 84
Rod B amp 50 114 39 24 0 69 187 145
Rod B IT 88 85 9 4 72 79 108 93
Max com amp 193 321 107 37 0 257 420 363
Max com IT 42 39 8 2 31 36 57 42
Cone 30 Hz amp 34 55 21 12 0 34 73 69
Cone 30 Hz IT 34 30 6 1 26 29 54 32
SF cone amp 76 87 44 13 0 65 159 107
SF cone IT 28 29 5 0 14 28 35 29
Dark adaptometry 3 1 1 7
Amplitudes (amp) are in microvolts, and implicit times (IT) are in milliseconds.
TABLE 3. Frequency of Haplotypes in trans in the Two Groups
Haplotypes
Group I,
PD (%)
Group II; CRD,
CACD, & RP (%) Total (%)
C-A-A 13 (29.6) 0 (0) 13 (21)
G-A-G 31 (70.4) 17 (94.4) 48 (77.4)
C-G-A 0 (0) 1 (5.6) 1 (1.6)
Total 44 (71) 18 (29) 62 (100)
Group I with PD and milder phenotype (44 individuals) and Group
II with CRD, RP, and CACD with more severe phenotype (18
individuals). Skew in haplotype with Group I having more C-A-A
(29.6% vs. 0%) and Group II having more G-A-G (94.4% vs. 70.4%).
TABLE 4. Individuals Older than Age 43 Were Used for Statistical
Analysis and Continue to Exhibit the Skew in Haplotype
Haplotypes
Group I,
PD (%)
Group II; CRD,
CACD, & RP (%) Total (%)
C-A-A 8 (29.6) 0 (0) 8 (17.8)
G-A-G 19 (70.4) 17 (94.4) 36 (80.0)
C-G-A 0 (0) 1 (5.6) 1 (2.2)
Total 27 (60) 18 (40) 45 (100)
Fisher, P¼ 0.009; GEE analysis, 0.03.
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Gly338 haplotype among individuals with CRD, RP, and CACD
was significant with a relevant P value of <2e-16. However,
because the asymptotic P value may not be robust to the
‘‘zero’’ cell counts in two of the haplotype-phenotype
categories (see Tables 3, 4), we reran the GEE model taking
the conservative approach of collapsing the Gln304-Lys310-
Asp338 (C-A-A) and Gln304-Arg310-Asp338 (C-G-A) haplotypes
into a single category (P ¼ 0.03, N ¼ 45 due to removal of
individuals with age <43). The estimated odds ratio for this
comparison is 7.16 (95% CI ¼ [2.8–18.4]), suggesting that the
odds of having the CACD/RP-like phenotype (versus the PD
phenotype) are 7.16 times greater for affected individuals with
a Glu304-Lys310-Gly338 haplotype (G-A-G) haplotype in trans
than for affected individuals with one of the other two
haplotypes in trans (Gln304-Lys310-Asp338 [C-A-A] and Gln304-
Arg310-Asp338 [C-G-A]).
ROM1 Gene. No significant sequence variants were identi-
fied by bidirectional sequencing of ROM1 (NM_000327.3), in 10
affected individuals representing different phenotypes.
GUCA1A Gene. A GUCA1A (NM_000409.3), c.149C>T
(p.Pro50Leu), sequence variant was identified in 4 individuals
(3 affected—1 with macular atrophy and 2 with PD; 1
individual had normal retina) by bidirectional sequencing of
GUCA1A in 62 individuals.
FIGURE 4. Pattern dystrophy in a female aged 36 years (Fam8-6226). Milder vision loss and slow progression over a 9-year period, with relatively
preserved rod and cone function at age 45. Lower limits of normal (P < 0.05) are 85 lV for rod ERG, 200 lV for standard combined ERG, 50 lV for
30-Hz flicker ERG, and 75 lV for single flash cone ERG.
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NXNL1 Gene. Several variants including c.46G>A (p.As-
p16Asn), c.83G>C (p.Arg28Pro), c.172_174delTTC, (p.del-
Phe58), c.190G>A (p.Glu64Lys), and c.461A>T (p.Glu154Val),
were identified by bidirectional screening of NXNL1
(NM_138454.1) in 62 affected individuals and 103 CEPH
normal controls. However, none showed any significant
association.
DISCUSSION
This study demonstrated that the c.828þ3A>T splice site
mutation in the PRPH2 gene is the primary cause of retinal
disease in all 62 affected individuals in these 19 families with
complete penetrance but highly variable expressivity. It results
in clinically diverse, autosomal dominant retinal dystrophies,
including PDs, CRD, CACD, and RP (Figs. 1, 2), in 19 families
derived from a common ancestor.2 The phenotypes fall into
two broad clinical categories: Individuals in Group I (N ¼ 44;
AVMD, BMD, and AOFMD types of PD) have milder disease
than individuals in Group II (CRD, CACD, and RP). There is
limited progression from Groups I to II. In our cohort, almost
all individuals had reduced photoreceptor responses relative to
age-matched controls, regardless of the phenotype (Fig. 3).
We previously had established a founder effect for the
PRPH2 c.828þ3A>T mutation by haplotype analysis which
FIGURE 5. Retinitis pigmentosa in a male aged 48 years (Fam1-365). Rapid progression over a 20-year period from relatively preserved
photoreceptors and RPE to a complete loss of rod and greatly reduced cone function. Lower limits of normal (P < 0.05) are 85 lV for rod ERG, 200
lV for standard combined ERG, 50 lV for 30-Hz flicker ERG, and 75 lV for single flash cone ERG.
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excludes sequence variants in cis within 5 megabases of the
PRPH2 locus as modifiers.2 In this study, we analyzed the
haplotypes in trans and showed that Gln304-Lys310-Asp338
(C910-A929-A1014) is significantly associated with Group I
pattern dystrophies and Glu304-Lys310-Gly338 (G910-A929-G1013)
with Group II (P value ¼ 0.03 taking family structure,
progression with age and restricting our analysis to only
individuals (N¼ 45) older than 43 years of age. This suggested
the possible modifier role of the polymorphic protein
haplotypes in trans, with an estimated 7.16-fold increase in
the odds of the more severe phenotype for affected individuals
harboring a Glu304-Lys310-Gly338 (G-A-G) haplotype in trans
compared to other affected individuals, and a possible
protective role for having a second Gln304-Lys310-Asp338 (C-A-
A) haplotype in trans. Given that the two alleles are similar in
their temporal and spatial expression and interact directly, the
protein haplotype in trans is likely to contribute to the
phenotypic variation seen in the PRPH2 splice site mutation
families.
Several sequence variants were found in the other potential
modifier genes that were screened; however, none of them had
a significant association with any one phenotype. Progressive
photoreceptor loss with age explains continued vision loss in
some individuals. Another possible modifier may be variations
in expression of normal versus aberrant transcripts due to
leaky aberrant splicing.2 Functional studies with more accurate
quantification of the truncated protein and its interaction with
different RDS protein mini-haplotypes may help determine the
effect of variable splicing and protein mini-haplotypes in
modifying the retinal phenotype. Future studies with larger
number of patients and whole exome sequencing of additional
retinal disease-causing genes and/or whole exome and genome
sequencing may identify additional modifiers.
This study demonstrated the variability of autosomal
dominant retinal dystrophies resulting from PRPH2 mutations
and the possibility of common polymorphic protein variants
functioning as modifiers of disease-causing mutations in
Mendelian disorders. Determining the protein haplotype in
trans in these families may help predict the severity of the
retinal phenotype and may aid in counseling of the families.
The potential for splice site modification also is of therapeutic
interest in preserving vision in the affected individuals and
needs further evaluation.
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